Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Assaad MA, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, et al. Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. Front Oncol. 2023;13:1274163.

Potter RF, Zhang K, Reimler B, Marino J, Muenks CE, Alvarado K, et al. Uncharacterized and lineage-specific accessory genes within the Proteus mirabilis pan-genome landscape. mSystems. 2023;8(4):e0015923.

Limberg J, Lee-Saxton YJ, Egan CE, AlAnazi AA, Easthausen I, Stefanova D, et al. Perineural Invasion in Papillary Thyroid Cancer: A Rare Indicator of Aggressive Disease. Ann Surg Oncol. 2023;30(6):3570-3577.

Li JJ, Vasciaveo A, Karagiannis D, Sun Z, Chen X, Socciarelli F, et al. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer. bioRxiv. 2023.

Panarelli NC, Hornick JL, Yantiss RK. What Is the Value of Counting Mast Cells in Gastrointestinal Mucosal Biopsies? Mod Pathol. 2023;36(2):100005.

Hwang JK, Bakotic WL, Gold JA, Magro CM, Lipner SR. Isolation of Terbinafine-Resistant Trichophyton rubrum from Onychomycosis Patients Who Failed Treatment at an Academic Center in New York, United States. J Fungi (Basel). 2023;9(7).

Boyraz B, Gogakos T, Raskin KA, Nielsen GP. Metastatic Uterine Leiomyosarcoma With Rhabdomyosarcomatous Heterologous Differentiation. Int J Gynecol Pathol. 2023;42(2):151-154.

Bhattacharya U, Kamran M, Manai M, Cristofanilli M, Ince TA. Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers (Basel). 2023;15(2).

Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, et al. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. Blood Adv. 2023;7(20):6211-6224.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. bioRxiv. 2023.